Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
155
resultados
Última actualización
23/08/2025 [06:52:00]
Resultados 75 a 100 de 155
Resumen de: US2025255808A1
Biologics, including peptides, proteins, antibodies, nucleic acids (DNA and RNA), oligonucleotides, vaccines, or complex combinations of these substances, are important for treating various types of diseases and tissue and organ regeneration. However, biologics are not stable and have short half-lives, making effective delivery to patients difficult. Therefore, there is an unmet need in the art to increase the stability and half-lives of biologics for long-term bioavailability, therapy, treatment and repair. This invention provides a nanogel platform technology that can load biologics in aqueous solution with high loading efficiency without using any organic solvent and also sustain the release of active biologics in the body for more than 2 months.
Resumen de: US2025255830A1
A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.
Resumen de: WO2025171237A1
Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.
Resumen de: WO2025168810A1
Lipid composition comprising: (i) one or more cationic lipids, preferably cationically ionizable lipids, (ii) one or more phospholipids, and (iii) one or more statistical copolymers comprising repeating units of the following formula (I-a) and repeating units of formula (II-a) wherein R1 represents a hydrogen atom or a group selected from a C1-3 alkyl group, a cyclopropyl group, and a C3 alkenyl group; R2 represents a group selected from a saturated C4-40 hydrocarbyl group; an unsaturated C4-40 hydrocarbyl group having one or more carbon-carbon double and/or triple bonds; a saturated C4-40 heterohydrocarbyl group containing 1 to 5 divalent groups selected from ether, thioether, sulfone, sulfoxide, keto, ester, amide, carbamate and carbonate groups, and/or 1 to 5 fluorine atoms as substituents; and an unsaturated C4-40 heterohydrocarbyl group having one or more carbon-carbon double and/or triple bonds, and containing 1 to 5 divalent groups selected from ether, keto, ester, and carbonate groups and/or 1 to 5 fluorine atoms as substituents; and x and y independently represent 0 or 1.
Resumen de: WO2025168254A1
The present invention relates to functionalised nanoparticles. The present invention also relates to compositions comprising the functionalised nanoparticles, kits, processes for preparing nanoparticles, methods of treating cancer (including prostate cancer), imaging methods, diagnostic methods, methods for killing or attenuating the growth of a cancer cell in vitro, nanoparticles and compositions for use in the treatment of cancer or diagnosis, and a novel pepducin.
Resumen de: WO2024133486A1
The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.
Resumen de: KR20250122777A
기존 침투성 단백질 물질은 생체 내 분해, 흡수, 배출 등 약물동태학의 한계로 인하여 의약품 개발에 어려움이 있다. 따라서 알부민과 세포 침투성 펩타이드(Cell-Penetrating Peptide; CPP)를 이용하여 만든 세포 투과성 나노입자가 기존 세포 침투성 펩타이드의 한계를 극복하고 유용하게 쓰일 수 있음을 확인하고 본 발명을 완성하였다.
Resumen de: WO2025170309A1
The present invention relates to an optogenetic anti-inflammatory composition containing, as an active ingredient, nanoparticles including an agent for inhibiting the formation of the nod-like receptor protein 3 (NLRP3) inflammasome, wherein the nanoparticles contain: a vector including a polynucleotide encoding a truncated version of cryptochrome-interacting basic-helix-loop-helix 1 (CIBN)-NLRP3 fusion protein; and a vector including a polynucleotide encoding the cryptochrome 2 (CRY2) protein or a variant thereof. The optogenetic anti-inflammatory composition has excellent anti-inflammatory activity due to non-invasive light stimulation and can thus be highly effectively used in related fields.
Resumen de: AU2025208550A1
The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution. The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution. ul h e p r e s e n t i n v e n t i o n p r o v i d e s a n i m p r o v e d p r o c e s s f o r l i p i d n a n o p a r t i c l e f o r m u l a t i o n u l a n d m e n c a p s u l a t i o n n s o m e e m b o d i m e n t s , t h e p r e s e n t i n v e n t i o n p r o v i d e s a p r o c e s s f o r e n h a n c e d e n c a p s u l a t i o n o f m e s s e n g e r ( m ) i n l i p i d n a n o p a r t i c l e s c o m p r i s i n g a s t e p o f h e a t i n g t h e m - e n c a p s u l a t e d l i p i d n a n o p a r t i c l e s i n a d r u g p r o d u c t f o r m u l a t i o n s o l u t i o n
Resumen de: AU2024248582A1
The present invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal according to which: - a first composition/solution 1 containing an aluminum source and a source of an ion of an alkali metal M, in particular K, is prepared; a second composition/solution 2 comprising a silicon source and a source of an ion of an alkali metal M, in particular K, is prepared, said compositions/solutions 1 and 2 being free of any organic structuring agent; - the two compositions/solutions 1 and 2 are mixed; - the mixture is crystallized; and - said nanoparticles thus formed are optionally separated. According to the invention, said first composition/solution 1 and said second composition/solution 2 are both constituted of said source and of the aqueous saline phosphate buffer. The present invention also relates to colloidal suspensions of the nanoparticles obtained and to a pharmaceutical composition containing said nanoparticles.
Resumen de: TW202438045A
The present disclosure relates to a lipid compound of formula (AL-GI):, having various cleavable linkers defined by the variables Z1 and Z2. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering a therapeutic agent.
Resumen de: AU2024217713A1
Novel ionizable lipid compounds of Formula I-Het, Formula I and Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
Resumen de: WO2025171027A1
Compositions comprising multiple pHLIP® peptides linked to a lipid nanoparticle encapsulating one or more nucleic acids (pHLIP®-LNP) and methods of preparing the pHLIP®-LNPs are described.
Resumen de: US2025171786A1
Provided herein, in various embodiments, are methods and compositions comprising a Signal Regulatory Protein Alpha (SIRPα) therapeutic. In certain embodiments, the disclosure provides for methods and compositions for modulating SIRPα expression. In certain embodiments, the methods and compositions are useful in the treatment of a SIRPα-mediated disease or condition.
Resumen de: US2023331767A1
A compound of the formula (I): G1-L-G2, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein G1 is a folate radical, an antifolate radical, or a folate analog radical; L is a linker; and G2 is a radical of a steroid; compositions comprising such compounds; and the use of such compounds and compositions to treat, for example, inflammation associated with a disease or disorder.
Resumen de: GB2638046A
An ultrasound-responsive nanoscale delivery platform is disclosed for use in treating biofilm-associated diseases. It has been found that the use of a phase-shift nanodroplet/antimicrobial complex platform confers a number of advantages when used in methods for anti-biofllm therapy. Specifically, the inclusion of antimicrobials within the supramolecular structure of the ultrasound-responsive nanoscale delivery platform allows for increased passive cellular and subcellular uptake, stimuli-responsive spatiotemporally controlled drug release, and significantly higher bacterial toxicity in both planktonic cultures and mature biofilms. This platform remains stable in storage at room temperature, in blood components, and does not significantly prematurely release its loaded cargo. The platform may be used as a novel treatment option in biofilm-associated diseases such as, but not limited to, bone and joint infections, cystic fibrosis-associated pleural infections, chronic wounds, and chronic urinary tract infections.
Resumen de: AU2023356193A1
The disclosure relates to nucleic acid-based vaccines for cancer and other diseases.
Resumen de: WO2025170320A1
Disclosed herein are mesoporous ceria nanoparticles for the prevention, treatment, or alleviation of ophthalmic diseases. In one aspect, having mesoporous structure with high surface area and pore size and mimicking the catalytic properties of catalase and superoxide dismutase (SOD), the mesoporous ceria nanoparticles of the present invention have excellent ability to scavenge reactive oxygen species, exhibit anti-inflammatory effects, demonstrate biocompatibility without causing acute side effects or ocular toxicity in the retina, and are recognized to provide protective effects against cellular damage and protect damaged retinal pigment epithelial (RPE) cells and photoreceptors under high oxidative stress. Therefore, the nanoparticles can be utilized for the prevention, treatment, or alleviation of macular degeneration and various oxidative stress-mediated ophthalmic diseases.
Resumen de: WO2024075089A1
The present invention discloses a hybrid metal-lipid nanoparticle for targeted therapy comprising properties of organic and inorganic nanoparticles (NPs), combined in a single formulation to obtain NPs with unique attributes. This will allow the synergistic effect between drug delivery (also known as chemotherapy) and photothermal therapy. This strategy relies on the construction of hybrid metallic- gold nanoparticles using a dual functionality by lipid nanoparticles (as organic components and drug delivery system) in the core and gold nanorods (as inorganic component and a heat delivery system) in the shell, linked by a tumor-targeting peptide. The active targeting strategy was implemented to guarantee a specific delivery to the brain by using transferrin (targeting the blood-brain barrier) and cRGDfK (not only used to target GB tumor barrier but also as a linker between both inorganic and organic nanoparticles). The invention relates to the field of medicine and biotechnology. The present solution aims at developing targeting hybrid metal-lipid nanoparticle for the treatment of different types of cancer, including glioblastoma, envisioning the establishment of an in vitro/in vivo correlation.
Resumen de: CN119997932A
Micellar compositions comprising hedgehog pathway inhibitors and their use in the treatment of skin diseases, skin conditions or skin disorders such as skin cancer, including basal cell cancer, are disclosed.
Resumen de: AU2023357320A1
The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g., but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g., in combination with a chemotherapeutic agent). The present disclosure further provides RNA backbones containing specific sequences upstream and/or downstream from the coding sequence.
Resumen de: WO2025170343A1
The present invention provides: an ectosome comprising a corona-virus spike protein, wherein the ectosome exhibits improved drug delivery efficiency to lung cancer cells without side effects, and thus exhibits excellent anticancer efficacy; and a use thereof.
Resumen de: MX2025008379A
The present disclosure relates to hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors encoding a hMPV F, PIV3 F and PIV1 F protein mutant, compositions comprising a hMPV F, PIV3 F and PIV1 F protein mutant or nucleic acid, and uses of the hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors, and compositions.
Resumen de: WO2025170342A1
The present invention provides stem cell-derived membrane vesicle-liposome fusion nanoparticles and a use thereof, the nanoparticles exhibiting tumor site targeting ability and anticancer efficacy superior to those of a conventional drug delivery system having targeting ability.
Nº publicación: JP2025118829A 13/08/2025
Solicitante:
アーディジェン，エルエルシー
Resumen de: CN117431234A
The name of the invention is peptides and nanoparticles for intracellular delivery of genome editing molecules. The present invention relates to peptide-containing complexes/nanoparticles that can be used to stabilize and/or deliver one or more genomic editing system molecules, such as proteins and/or nucleic acids, such as CRISPR proteins and/or nucleic acids.
BOPI
Sede Electrónica
